Ionis bags a $75M milestone from Bayer; Inventiva garners $51M from IPO
• Ionis Pharmaceuticals $IONS is picking up a $75 million milestone payment from Bayer related to IONIS-FXIRx. Ionis plans to start a Phase IIb study with IONIS-FXIRX in patients with end-stage renal disease who are on hemodialysis. “We recently completed a Phase II study in patients with end-stage renal disease on hemodialysis, in which IONIS-FXIRx demonstrated robust reductions in Factor XI activity and no treatment-related major bleeding, ” stated B. Lynne Parshall, COO at Ionis Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.